Our group is dedicated to translational research focusing on three key areas of interest. First, we investigated prognostic and predictive factors related to targeted and immune therapies. Our goal is to identify biomarkers that will help predict which patients will respond best to these therapies, allowing us to offer more personalized treatment options and improve patient outcomes.
Second, we are generating patient-derived models that are relevant for preclinical research. Finally, we are conducting preclinical and clinical evaluations of novel therapeutic strategies. We are particularly interested in developing molecular therapies targeting altered signaling pathways in pancreatic and biliary tract cancers. Our group has made significant contributions in this field, pioneering early phase clinical trials to advance anticancer strategies against cancers of the upper gastrointestinal tract and associated translational studies.
